{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:45:19Z","timestamp":1757623519832,"version":"3.44.0"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:00:00Z","timestamp":1757289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>In recent years, continuous intraperitoneal insulin infusion (CIPII) has become a valid therapeutic option to achieve good glycemic control for patients with unstable type 1 diabetes and subcutaneous insulin resistance, mainly due to the absorption of insulin through the portal venous system. This route improves hepatic uptake and reduces peripheral plasma insulin levels, also optimizing glucagon secretion and hepatic glucose production. CIPII can lead to better blood glucose control and more predictable insulin profiles, especially after meals, compared to subcutaneous injections. Therefore, some studies suggest that CIPII may reduce the risk of hypoglycemia compared to subcutaneous insulin as well as improving patient satisfaction. Actually, among CIPII delivery systems, DiaPort particularly stands out for its low side effects, proven clinical efficacy, and potential for integration into closed-loop systems.<\/jats:p>","DOI":"10.3389\/fmed.2025.1657069","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:13:02Z","timestamp":1757401982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous intraperitoneal insulin infusion as a valuable approach in patients with unstable type 1 diabetes: two case reports and a mini review of the literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Erika","family":"Pedone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Caretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Belfiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Zanardini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Di Molfetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Laviola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Piemonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Scavini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Laurenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1177\/1932296817694913","article-title":"A new optimized percutaneous access system for CIPII","volume":"11","author":"Garcia-Verdugo","year":"2017","journal-title":"J Diabetes Sci Technol"},{"key":"ref2","volume-title":"Evaluation of the new ACCU-CHEK\u00ae DIAPORT system, a port system for continuous intraperitoneal insulin infusion, in patients with type 1 diabetes: Final 12-month results","author":"Liebl","year":"2016"},{"key":"ref3","first-page":"190","volume-title":"Technological advances in the treatment of type 1 diabetes","author":"Bruttomesso","year":"2015"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/j.1463-1326.2009.01059.x","article-title":"A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion","volume":"11","author":"Liebl","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.2337\/dc08-2340","article-title":"Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial","volume":"32","author":"Logtenberg","year":"2009","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.2337\/dc09-1758","article-title":"Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomized controlled trial","volume":"33","author":"Logtenberg","year":"2010","journal-title":"Diabetes Care"},{"key":"ref7","first-page":"738","article-title":"Peritoneal and subcutaneous absorption of insulin in type 1 diabetec subjects","volume":"77","author":"Giacca","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/dmrr.961","article-title":"Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control","volume":"25","author":"Radermecker","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/BF00400727","article-title":"Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices","volume":"38","author":"Jeandidier","year":"1995","journal-title":"Diabetologia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2337\/diacare.17.8.847","article-title":"A cost-benefit comparison of intensive diabetes management with implantable pumps versus multiple subcutaneous injections in patients with type I diabetes","volume":"17","author":"Haardt","year":"1994","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1472-6823-14-30","article-title":"Continuous intraperitoneal insulin infusion in type 1 diabetes: a 6-year post-trial follow-up","volume":"14","author":"Van Dijk","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e0249611","DOI":"10.1371\/journal.pone.0249611","article-title":"Physiological effects of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: a systematic review and meta-analysis","volume":"16","author":"Dirnena-Fusini","year":"2021","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1089\/dia.2015.0001","article-title":"Continuous intraperitoneal insulin infusion versus subcutaneous insulin therapy in the treatment of type 1 diabetes: effects on glycemic variability","volume":"17","author":"Van Dijk","year":"2015","journal-title":"Diabetes Technol Ther"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabres.2013.09.007","article-title":"Glucose variability: an emerging target for treatment of diabetes mellitus","volume":"102","author":"Frontoni","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2337\/dc09-1080","article-title":"Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas","volume":"33","author":"Renard","year":"2010","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1111\/dom.12999","article-title":"Intraperitoneal insulin delivery provides superior glycaemic regulation to subcutaneous insulin delivery in model predictive control-based fully-automated artificial pancreas in patients with type 1 diabetes: a pilot study","volume":"19","author":"Dassau","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.4239\/wjd.v3.i8.142","article-title":"Complications of continuous intraperitoneal insulin infusion with an implantable pump","volume":"3","author":"Van Dijk","year":"2012","journal-title":"World J Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1046\/j.1464-5491.2002.00727.x","article-title":"Continuous intraperitoneal insulin infusion in patients with \u201cbrittle\u201d diabetes: favourable effects on glycaemic control and hospital stay","volume":"19","author":"DeVries","year":"2002","journal-title":"Diabet Med"},{"key":"ref19","volume-title":"Handbook for port users-The Accu-Chek DiaPort system","year":"2021"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1657069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:13:05Z","timestamp":1757401985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1657069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,8]]},"references-count":19,"alternative-id":["10.3389\/fmed.2025.1657069"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1657069","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,8]]},"article-number":"1657069"}}